Clark Laboratories, Inc. (dba,Trinity Biotech USA)
FDA classification date
Dec 26, 2013
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II
Reason stated in the source
Trinity Biotech recalled Trinity Biotech Captia Syphilis IgG kits due to false negative results.
Source facts
Action
Trinity Biotech issued an Urgent Product Information Request letter to their customer on August 27, 2013. The letter identified the affected product, problem and actions to be taken. The request was to determine if their customer did or did not backfill microtiter-strips during the analytical process. If a customer backfilled, they were advised to return the completed request form. On September 11, 2013 Trinity Biotech issued a notice to their customers advising them to re-evaluate any negative patient results for those who perform backfilling. For questions contact Trinity Biotech Help Desk at 800-325-3424, option 2.
Initiated
2013-08-27
Root cause
Process design
Terminated
2016-05-24
Distribution
USA Nationwide Distribution in the state of WA
Recall number
Z-0572-2014
Recall status
Terminated
CDRH record ID
124185
FDA classified
2013-12-26
Recall event number
66916
Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.
Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.